title: Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules.
abstract: OBJECTIVE
  To compare the pharmacokinetics and site of uptake of budesonide from a controlled-release formulation and a deuterium-labelled standard formulation given before and after a meal.
  
  
  METHODS
  Six healthy volunteers were randomized into an open, crossover study. They received 4.5 mg controlled-release budesonide (mixed with In pellets to trace gastrointestinal transit) and 4.8 mg 2H8-budesonide simultaneously at each of two visits: one visit before a standardized breakfast and the other after breakfast. Plasma concentrations of budesonide were followed over 24 h. The transit of the (111)In pellets through the gastrointestinal tract was followed for 36 h. Data on the site of absorption were calculated from transit times and absorption curves.
  
  
  RESULTS
  The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h). When given after breakfast, the controlled-release formulation was associated with a mean residence time 1.6 h longer than that seen with the standard formulation. However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l). Over 60% of the total budesonide absorbed from controlled-release capsules was delivered and absorbed in the ileum and colon. The corresponding proportion for the standard formulation was approximately 33%.
  
  
  CONCLUSIONS
  Controlled-release budesonide effectively delivers most of the budesonide dose to the ileum and colon, the regions that are most often affected by inflammatory bowel disease. In addition, the time of food intake has little effect on the site of absorption or the bioavailability of the controlled-release formulation. Delivery to the colon and ileum was independent of whether the drug was given before or after breakfast.
authors.affiliation: Experimental Medicine, AstraZeneca Pharmaceuticals LP, Wayne, Pennsylvania 19087, USA. staffan.edsbacker@astrazeneca.com
authors.forename: Staffan
authors.initials: S
authors.lastname: Edsbäcker
authors.forename: Per
authors.initials: P
authors.lastname: Larsson
authors.forename: Per
authors.initials: P
authors.lastname: Wollmer
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D019819:Budesonide / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002214:Capsules; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D005260:Female; D005772:Gastrointestinal Transit; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008297:Male; D008875:Middle Aged
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D019819:Budesonide